Tackling corruption in the health sector: the role of the Medicines Transparency Alliance (MeTA)
Upcoming SlideShare
Loading in...5
×
 

Tackling corruption in the health sector: the role of the Medicines Transparency Alliance (MeTA)

on

  • 3,203 views

Presentation from the Medicines Transparency Alliance (MeTA) at the 13th International Anti-Corruption Conference, held in Athens, Greece, November 2008. This highlights the way in which MeTA is ...

Presentation from the Medicines Transparency Alliance (MeTA) at the 13th International Anti-Corruption Conference, held in Athens, Greece, November 2008. This highlights the way in which MeTA is working in 7 countries to improve acess to medicines through greater transparency and accountability around the way in which medicines are purchased and used.

Statistics

Views

Total Views
3,203
Views on SlideShare
3,194
Embed Views
9

Actions

Likes
0
Downloads
57
Comments
0

3 Embeds 9

http://www.slideshare.net 7
http://translate.googleusercontent.com 1
http://www.health.medicbd.com 1

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Title of presentation 06/06/09 MeTA

Tackling corruption in the health sector: the role of the Medicines Transparency Alliance (MeTA) Tackling corruption in the health sector: the role of the Medicines Transparency Alliance (MeTA) Presentation Transcript

  • Andrew Chetley Communication Director MeTA Secretariat Medicines Transparency Alliance: helping markets work for the poor MeTA 06/06/09
  • MeTA numbers
    • 26 key supporters (governments and organisations)
    • 10 broad principles
    • 7 pilot countries
    • 3 essential stakeholder sectors
    • 2 major commitments
    • 4 areas of information disclosure
    • 1 goal: improve access to essential medicines for the 2 billion people who currently lack access
    06/06/09 MeTA
  • 26 supporters of the objective of increased equitable access to medicines
    • Association of the British Pharmaceutical Industry
    • AstraZeneca
    • Co-operative Investments
    • Ecumenical Pharmaceutical Network
    • F&C Investments
    • GlaxoSmithKline
    • Government of Peru
    • Government of the Hashemite Kingdom of Jordan
    • Government of the Kyrgyz Republic Government of the Republic of Ghana
    • The Government of the Republic of the Philippines
    • Government of the Republic of Uganda
    • Government of the United Kingdom
    • Government of the Republic of Zambia
    • Health Action International Global
    • Indian Pharmaceutical Association
    • Institute for Democracy in South Africa
    • International Federation of Pharmaceutical Manufacturers and Associations
    • International Pharmaceutical Federation
    • Merck
    • Novartis
    • Partnership for Supply Chain Management
    • SustainAbility
    • Transparency International
    • World Bank
    • World Health Organization
    • … and growing daily …
    06/06/09 MeTA View slide
  • 10 Principles
    • Good health is crucial to human dignity and to social and economic development.
    • Efforts to improve health depend on effective health systems
    • Inefficient procurement, distribution, and supply of medicines, weak regulation and poor supply chain management, and lack of information can result in unaffordable/unavailable medicines.
    • Urgent action is required to address these challenges.
    • Public understanding could inform public debate, enhance public policy and drive improvements
    • High standards of transparency can build trust and accountability .
    • A multi-stakeholder approach can build understanding on how to develop greater transparency and accountability.
    • Action to increase transparency and accountability should do no harm, support national development and harmonisation plans, respect the rule of law and be guided by concerns for social justice,
    • We recognise the need to pilot and evaluate these actions.
    • Our ultimate objective is to increase equitable access to medicines.
    06/06/09 MeTA View slide
  • 7 Pilot Countries
    • … pioneers, leaders, champions – innovators!
    • … and an International Advisory Group
    06/06/09 MeTA
  • 3 key stakeholder sectors
    • Public: (ministries – not only Health; health service managers and facilities; regulatory agencies; health and welfare insurance schemes)
    • Private: (manufacturers; wholesalers; distributors; retailers; private practitioners and services; private health insurance; investors)
    • Civil society: (communities, patients, consumers, transparency and rights groups, media, faith-based organisations)
  • 2 major commitments
    • Progressive disclosure of data in four areas
    • Development of an effective multi-stakeholder forum
      • ‘ All too often, government planners, business executives, and non-profit organisations have operated at cross-purposes and failed to coordinate their efforts in ways that would achieve shared goals.’ (Gupta, R. 2007. Health International, McKinsey & Co.)
      • … transparency and (mutual) accountability
  • 4 disclosure areas; 4 contextual areas
    • Quality
    • Availability
    • Price
    • Promotion
    • Supply chain operations
    • Medicine affordability
    • Equitable access
    • Rational use
  • One goal
    • Increased access to essential medicines by poor people by:
      • shifting some decision making power
      • Increasing competitive pressure on suppliers
      • Improving the effectiveness of the supply chain
      • promoting better governance
      • ensuring more appropriate resource allocation
      • encouraging innovative and responsible business practices
      • Increasing the voice of patients and consumers
    • And improving people’s health!
  • Complexity: of the medicines supply system 06/06/09 MeTA Source: SSDS Inc for the World Bank
  • innovation new and different voices equity dynamic dialogues transformation different perspectives problem solving mutual accountability changing business practice social justice new partnerships transparency Complexity: of change
    • 18 months planning and consensus building
    • 7 countries commit politically
    • Growing list of international stakeholders who support the concept
    • International Secretariat in place
    • International Advisory Group underway
    • International launch – “2 nd phase of the peaceful revolution in international public health” now underway!
    Achievements so far MeTA 06/06/09
  • Peru: health insurance company brings down the price of medicines by 30% - who benefits? Uganda: 50% of medicines for the public sector are found in the private sector – who pays twice? Jordan: high prices include a government tax – united voices for change Philippines: 2000 separate procurement approaches – how to avoid conflict of interest? Four stories of change MeTA 06/06/09
    • How do we engage with new stakeholders (at every level) to increase support for the concept?
    • How do we work with the diversity at national level, yet still have meaningful sharing of lessons internationally?
    • How do we work towards multiple bottom lines: everyone wins (everyone prepared to give something away)?
    • What does success look like? (How will we know it has worked?)
    Challenges we face MeTA 06/06/09
  • More information
    • Contact the MeTA Secretariat
      • International Secretariat, [email_address]
      • Andrew Chetley, [email_address]
      • www.MedicinesTransparency.org
      • and have your say: join in to MeTA-Dialogue – an interactive discussion group at:
      • www.dgroups.org/groups/MeTADialogue/index.cfm
    06/06/09 MeTA